Asieris Pharmaceuticals, a China-based oncology therapy developer backed by corporates C&D, SAIC and Tigermed, has completed a RMB700m ($106m) series D round led by venture capital firm Qiming Venture Partners, DealStreetAsia reported today.
Founded in 2010, Asieris is working on therapeutics for genitourinary tumours and its lead drug candidate, APL-1202, is currently in phase 3 clinical trials.
The round followed approximately $59m in series C-plus funding in June this year from medical researcher Tigermed, supply chain services firm C&D and Hengxu Capital, a fund of funds operated by carmaker SAIC’s corporate venturing unit, SAIC Capital, according to DealStreetAsia.
Yingke PE, BioTrack Capital, YF Capital, CICC Capital’s Chuanhua Fund, Noah Holdings’ Gopher Asset Management unit, IN Capital, V-Capital, Homsun Capital, IFSC, Triwise Capital and Haoshuo Zhier Fund also took part in the round.
Asieris had raised a nine-figure renminbi amount (RMB100m = $14.1m) three months earlier in a series C round led by Yanyuan Capital and backed by Guozhong Venture Capital, Efung Capital and cooperative funds for Lapam Capital and Kaitai Capital.
Both Lapam Capital and Kaitai Capital had previously contributed to a series B round for the company sized at more than RMB100m ($15.3m) in 2017.
